Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks (ticker: DNA) is a synthetic-biology company that designs and engineers microorganisms for customers across industries, from pharmaceuticals to agriculture and industrial chemicals. The business operates a cell‑programming platform and offers foundry services, partnerships and licensing to generate revenue. With a market capitalisation around $737.9m, Ginkgo is a small‑cap company that has invested heavily in R&D, capacity and acquisitions to expand its platform — a strategy that has weighed on near‑term profitability. Potential upside comes from scalable services, recurring revenues from partnerships and novel product opportunities, but the stock can be volatile: progress depends on scientific success, customer adoption, regulatory outcomes and capital markets. Investors should note the company’s development stage, potential for further fundraising and biotech sector risks. This information is educational only and not personal investment advice; consider your risk tolerance and seek professional advice before investing.
Stock Performance Snapshot
Analyst Rating
Analysts suggest selling Ginkgo Bioworks stock, expecting its price to remain below target value.
Financial Health
Ginkgo Bioworks is generating solid revenue, high profit margins, and strong cash flow per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring DNA
Synthetic-Bio Foundries
Discover companies that are programming living cells to create the materials of tomorrow. These carefully selected stocks represent pioneers in replacing petrochemical processes with cleaner, more efficient biological alternatives - essentially turning microbes into tiny manufacturing plants.
Published: June 17, 2025
Explore BasketCell & Gene Therapy Logistics
This carefully curated collection features companies providing the essential infrastructure that makes advanced cell and gene therapies possible. Selected by expert analysts, these stocks represent the "picks and shovels" of the biotech revolution—giving you exposure to regenerative medicine's growth without the direct risks of clinical trials.
Published: June 17, 2025
Explore BasketNew Moon Portfolio
This collection represents the very beginning of the next technological cycle. These carefully selected companies are sowing the seeds of future industries, giving you early exposure to disruptive innovators poised for exponential growth as their technologies reshape our world.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Platform potential
Ginkgo’s cell‑programming platform could unlock recurring services and licensing revenue as customers scale, though commercial outcomes and timing can vary.
Partnership momentum
Collaborations and agreements can accelerate revenue and validation, but returns depend on execution and may take time to materialise.
Science and regulation
Scientific progress and regulatory approvals shape long‑term value; investors should expect developmental and policy uncertainties.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
